scholarly journals PMS15 Costs of Tumor Necrosis Factor Blockers per Treated Patient Across Adult Indications Using Real-World Data in US Commercially-Insured Population

2011 ◽  
Vol 14 (7) ◽  
pp. A304-A305
Author(s):  
V. Schabert ◽  
S.R. Gandra ◽  
C. Watson ◽  
K.M. Fox ◽  
J. Yeaw ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Treated Patient ◽  
Real World Data ◽  
World Data ◽  
Necrosis Factor

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

2011 ◽  
Vol 15 (2) ◽  
pp. 264-275 ◽  
Author(s):  
Vernon F. Schabert ◽  
Crystal Watson ◽  
Shravanthi R. Gandra ◽  
Seth Goodman ◽  
Kathleen M. Fox ◽  
...  
Keyword(s):  
United States ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
The United States ◽  
Tumor Necrosis Factor Inhibitors ◽  
Real World Data ◽  
World Data ◽  
Necrosis Factor

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

2013 ◽  
Vol 19 (8) ◽  
pp. 621-630 ◽  
Author(s):  
Vernon F. Schabert ◽  
Crystal Watson ◽  
George J. Joseph ◽  
Paige Iversen ◽  
Chakkarin Burudpakdee ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Managed Care ◽  
Real World ◽  
Tumor Necrosis ◽  
Treated Patient ◽  
Necrosis Factor

scholarly journals Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

2021 ◽  
Author(s):  
David L Kaplan ◽  
Brian L Ung ◽  
Corey Pelletier ◽  
Chuka Udeze ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Claims Data ◽  
Tumor Necrosis Factor Inhibitor ◽  
Total Cost ◽  
Factor Inhibitor ◽  
Treatment Data ◽  
Necrosis Factor

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

Sign in / Sign up

Export Citation Format

Share Document